About Bruker Cellular Analysis
Bruker Cellular Analysis is a company based in New Haven (United States) founded in 2012 was acquired by Berkeley Lights in December 2022. It operates as a Technology-as-a-Service and Professional Services. Bruker Cellular Analysis has raised $185.85 million across 16 funding rounds from investors including KeyBank, NIH and BlackRock. The company has 195 employees. Bruker Cellular Analysis offers products and services including Beacon Discovery™, IsoLight System, and T Cell Profiling Kit. Bruker Cellular Analysis operates in a competitive market with competitors including 10X Genomics, Guardant Health, Foundation Medicine, ArcherDX and Natera, among others.
- Headquarter New Haven, United States
- Employees 195
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website isoplexis.com
- Social LinkedIn
- Acquired by Berkeley Lights (Dec 2022)
- Legal Name Bruker Cellular Analysis
- Annual Revenue$16.76 M (USD)-3as on Dec 31, 2022
- Total Equity Funding$185.85M (USD)
in 16 rounds
- Latest Funding Round$92.5M (USD), Series D
Jan 2021
- InvestorsKeyBank
& 15 more
- Employee Count195
- Acquired byBerkeley Lights
(Dec 2022)
Products & Services of Bruker Cellular Analysis
Bruker Cellular Analysis offers a comprehensive portfolio of products and services, including Beacon Discovery™, IsoLight System, and T Cell Profiling Kit.
Live single-cell analysis is enabled for research purposes.
Single-cell proteomic signatures are captured for analysis purposes.
T cell functions are profiled for therapeutic discovery.
Funding Insights of Bruker Cellular Analysis
Bruker Cellular Analysis has successfully raised a total of $185.85M across 16 strategic funding rounds. The most recent funding activity was a Series D round of $92.5 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $185.85M
- Total Rounds 16
- Last Round Series D — $92.5M
- First Round $100,000
(Jun 2014)
- Investors Count 15
Latest 10 of 16 funding rounds of Bruker Cellular Analysis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | $50M | Debt – Conventional | – | – | |
| Jan 2021 | $92.5M | Series D | – | Perceptive Advisors | |
| Jun 2020 | $2M | Grant | – | – | |
| Jan 2020 | $20M | Series C | – | Northpond Ventures | – |
| Oct 2019 | $2M | Grant | – | – | |
| May 2019 | $25M | Series C | – | Northpond Ventures | |
| Nov 2018 | $19.65M | Series B | – | – | – |
| Oct 2017 | $1.8M | Grant | – | – | |
| Sep 2017 | $13.5M | Series B | – | Spring Mountain Capital | |
| Aug 2017 | $5.4M | Series B | – | – | – |
16 investors in total: 16 institutional.
Investors in Bruker Cellular Analysis
Bruker Cellular Analysis has secured backing from 16 investors, including venture fund and institutional investors. Prominent investors backing the company include KeyBank, NIH and BlackRock.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Private equity and hedge fund investments in healthcare are managed. | – | ally-bridge.com | Hong Kong, China | |
Venture capital firm investing in life sciences & tech sectors | – | npv.vc | Cambridge, United States | |
Private equity and debt investments are focused on multiple sectors. | – | ironwoodcap.com | Avon, United States | |
Venture capital services for biotech, IT, and innovative sectors in Connecticut. | – | ctinnovations.com | - | |
Venture capital fund focused on multiple sectors | – | smcgrowthcapital.com | New York, United States | |
Private equity investment firm | – | advantagecap.com | New Orleans, United States | |
An online gaming platform is operated in Macau. | – | yeifund.com | Macau | |
Diversified investment management firm and private fund focused on debt, equity, and secondary market investments in multiple sectors | 1988 | blackrock.com | New York, United States | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States |
Investor details for Bruker Cellular Analysis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Bruker Cellular Analysis
243 people are tracked at Bruker Cellular Analysis (75 in leadership, 10 in board & advisors, 158 in team); the tracked headcount is 195.
| Name | Role | Group |
|---|---|---|
Falko Busse | President, Bruker BioSpin Group | Leadership |
Christian Schürr | Head Of Factory And R&d Controlling | Leadership |
Frank Laukien | Chairman, President & CEO | Leadership |
Angela Mazzonetto | Chief Privacy Officer | Leadership |
Juergen Srega | President, Bruker CALID Group | Leadership |
Mark R. Munch | EVP & President, Bruker Nano Group & Bruker Nano Surfaces Division | Leadership |
Gerald N. Herman | EVP & Chief Financial Officer | Leadership |
Barbara Burgess | Vice President, Financial Operations & Project Management | Leadership |
Beata Adamczyk | Principal Finance Business Partner | Leadership |
Klaus Schlenga | Executive Vice President & CTO Bruker EST | Leadership |
Mark McMaster | Executive Vice President Of Operations, Bnano Group And Bruker Nano Surfaces Division | Leadership |
Niels Grote | Head Of Salesforce Competence Center | Leadership |
Matthias Boese | Vice President Compact Systems, Microscopy & Life Science | Leadership |
Daniel Hornburg | Vice President Biomarkers & Precision Medicine | Leadership |
Bjorn Johnson | Senior Vice President, Legal, And General Counsel, Bruker Nano Group | Leadership |
Kora Knuchel | Vice President, IP And Legal (lsms) | Leadership |
Shanil Govindpershad | Managing Director & GM Of Bruker SA (pty) Ltd & Head Of Commercial Operations For Africa | Leadership |
Jeffrey Zonderman | Senior Vice President | Leadership |
Phil Simmons | Vice President, Global Sales | Leadership |
Erica Forsberg | Vice President Metabolomics | Leadership |
223 more people are available in the full profile.
Complete people profiles for Bruker Cellular Analysis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Bruker Cellular Analysis
5 dated milestones of Bruker Cellular Analysis across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Bruker Cellular Analysis is founded.
- Funding First funding round of $100K.
- Funding Latest funding round, Series D, of $92.5M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Berkeley Lights.
Competitors of Bruker Cellular Analysis
Bruker Cellular Analysis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as 10X Genomics, Guardant Health, Foundation Medicine, ArcherDX and Natera, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| 10xgenomics.com | 2012 | Pleasanton, United States | $199.9M | 961 | Instrument systems for genomic research and sequencing libraries are developed. | |
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| strandls.com | 2000 | Bengaluru, India | $34.88M | 532 | Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery | |
| prenetics.com | 2009 | Hong Kong, China | $67.65M | – | Health risks are identified through online genetic and diagnostic testing. | |
| missionbio.com | 2014 | San Francisco, United States | $110M | 109 | Single-cell multi-omics platform is provided for genotypic and phenotypic analysis. | |
| veracyte.com | 2008 | San Francisco, United States | $67.9M | 815 | Genomics-based diagnostic tests for cancer are developed. |
Detailed competitors of Bruker Cellular Analysis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bruker Cellular Analysis
Complete news archive for Bruker Cellular Analysis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Bruker Cellular Analysis
10 companies that operate in the same segment as Bruker Cellular Analysis (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Bruker Cellular Analysis
Bruker Cellular Analysis was founded in 2012 and raised its 1st funding round 2 years after it was founded.
Bruker Cellular Analysis is headquartered in New Haven, United States. It is registered at New Haven, Connecticut, United States.
Bruker Cellular Analysis is a funded company, having raised a total of $185.85M across 16 funding rounds to date. The company's 1st funding round was a Series B of $5.4M, raised on Jun 2014.
Bruker Cellular Analysis has 195 employees.
Annual revenue of Bruker Cellular Analysis is $16.76M as on Dec 31, 2022.
Bruker Cellular Analysis is engaged in pioneering live single-cell, multimodal, and temporal functional analysis to accelerate scientific breakthroughs. Solutions are provided for antibody discovery, T cell profiling, and cell line development in the optofluidic domain. Proteomic barcoding tools are offered to capture cytokine and phosphoprotein signatures for disease prediction. The company serves sectors like cancer immunology, cell and gene therapy, infectious diseases, inflammation, neurology, and oncology. Platforms such as Beacon Discovery and IsoLight are designed for academic, translational, and biotech research labs.
Bruker Cellular Analysis's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
Bruker Cellular Analysis offers Beacon Discovery™, IsoLight System, and T Cell Profiling Kit.
Bruker Cellular Analysis has 16 investors. Key investors include KeyBank, NIH, BlackRock, Yale University, and Berkeley Lights.
Bruker Cellular Analysis operates through Bruker Cellular Analysis.
Yes. Bruker Cellular Analysis was acquired by Berkeley Lights in December 2022.